The pipeline and market for psoriasis drugs

Psoriasis is a chronic T-lymphocyte-mediated inflammatory disorder that affects 2–3% of the population globally. It is associated with abnormal keratinocyte proliferation, and is clinically characterized by erythematous, clearly demarcated papules and rounded plaques. Approximately 75% of patients with psoriasis will have at least one comorbid condition, with psoriatic arthritis being the most common.

Source link